Pelthos Therapeutics Inc.

Stage 4 · Declining · week 3

As of Oct 22, 2026, Pelthos Therapeutics is in Stage 4, the downtrend phase, now in week 3 (since Oct 2, 2026). It closed at $19.59, 47.6% below its 52-week high and below its 200-day average, which is falling.

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. More about the company

$19.59

+5.04% today

$75.0M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is PTHS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-02-16 → 2026-10-22

S? 41w

S3 13w

S2 21w

S3 14w

2024-02-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S4 5w → S1 4w → S2 9w → S3 13w → S2 21w → S3 14w → S4 7w → S1 9w → S2 9w → S3 4w → S4 3w current

Total tracked: 140 weeks across 12 stage runs.

PTHS among Biotechnology309th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…309	PTHSPelthos Therapeutics Inc.	Stage 4 · wk 3	30	−16.7%

vs 52W High

-47.6%

$18.19 lo$37.42 hi

47.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 3

1w13w26w

Week 3, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-20.2%

200 DMA: $24.54 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.80x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-16.7%

-24.4%

-15.6%

YTD

-33.5%

-36.8%

Scan Membership

Breakout Watch

Latest: 2025-02-04

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 3 · Vol 1.80x

2026-10-21S4

Wk 3 · Vol 2.26x

2026-10-20S4

Wk 3 · Vol 1.81x

2026-10-19S4

Wk 3 · Vol 2.00x

2026-10-16S4

Wk 3 · Vol 1.80x

2026-10-15S4

Wk 2 · Vol 1.45x

2026-10-14S4

Wk 2 · Vol 1.03x

2026-10-13S4

Wk 2 · Vol 1.05x

2026-10-12S4

Wk 2 · Vol 1.03x

2026-10-09S4

Wk 2 · Vol 0.79x

2026-10-08S4

Wk 1 · Vol 1.18x

2026-10-07S4

Wk 1 · Vol 0.30x

Moving averages & range

50 DMA

$22.81

200 DMA

$24.54

52W High

$37.42

52W Low

$18.19

5D Low

$18.65

Resistance levels (recent highs)

20d High

$22.19

60d High

$29.45

120d High

$29.50

250d High

$37.42

Next resistance

+13.3%

to 20d High

Dividend Yield

0.00%

P/B -48.5

Pelthos Therapeutics: quick answers

What stage is Pelthos Therapeutics in?

As of Oct 22, 2026, Pelthos Therapeutics (PTHS) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 2, 2026 and is in week 3. What the four stages mean

Is Pelthos Therapeutics in an uptrend?

No. Pelthos Therapeutics is in a Stage 4 downtrend. It trades 20.2% below its 200-day average, which is falling.

How far is Pelthos Therapeutics from its 52-week high?

Pelthos Therapeutics closed at $19.59 on Oct 22, 2026, 47.6% below its 52-week high of $37.42. Its 52-week low is $18.19.

How has Pelthos Therapeutics performed over the past year?

As of Oct 22, 2026, Pelthos Therapeutics is down 36.8% over the past year and down 33.5% so far in 2026.

Which sector and industry is Pelthos Therapeutics in?

Pelthos Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.